Findings by leading researchers demonstrate the promise and relevance of Simoa in vast application areas BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully ...

LEXINGTON, Mass., Oct. 11, 2012 /PRNewswire/ -- Quanterix Corporation announced today that the Journal of Virological Methods published a key study describing the application of its ultra-sensitive ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay ...

Record-breaking number of presentations and abstracts at International Multiple Sclerosis conference demonstrates promise and relevance of Neurofilament light chain (Nf-L) as a reliable disease ...

Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it had been issued a US Patent for ultra-sensitive detection of molecules. The patent issue marks ...

Companies expect to launch a product for the life sci market by 2013 and for the IVD segment by 2014. Stratec Biomedical has agreed to co-develop and manufacture a full automated version of Quanterix’ ...

LEXINGTON, Mass. Quanterix Corporation, a leader in high definition diagnostics, today announced that The Journal of Clinical Chemistry has published a new study in which its single molecule array ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa technology ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...